Here you will find a range of CSF podcasts recorded by our steering committee members and other notable authors.
Prof Iain McInnes discusses the use of baricitinib to treat COVID-19 and a JAK inhibitor, itacitinib. Keep up-to-date with the latest information in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor of Rheumatology at University Medical Centre, Utrecht. In this podcast, Professor Bijlsma discusses what attracted him to the field of rheumatology, the major advances in immunological knowledge leading to tsDMARDs and the importance of Treat-to-Target. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research, and views on developments in inflammation.
Professor of Rheumatology in the Department of Internal Medicine - Hospital de Clínicas at the Federal University of Paraná, Brazil. In this podcast, Professor Azevedo discusses what attracted him to rheumatology and how biosimilars have evolved in Latin America.
Kevin Winthrop, Professor of Infectious Diseases and Public Health at the Oregon Health & Science University in Portland, Oregon. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Winthrop discusses infections in baricitinib clinical trials for patients with active RA.
Prof Iain McInnes discusses the risk of infection and cardiovascular events associated with JAK inhibitors.
Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Dr Pedro López-Romero, a senior research scientist from Lilly, and Dr Eugen Feist from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, they discuss anti-CarbV and anti-MCV titres as predictors for improvements in SDAI score and radiographic progression in patients with RA.